Together, we’ll achieve more.

Improving upon existing SureSeq technology, this latest SureSeq NGS panel unlocks more efficient and expansive genetic profiling for CLL samples. The figure (right) illustrates the panel's uniformity and high depth of coverage, allowing the confident detection of [A] a SF3B1 exon 15 hotspot variant Lys700Glu with 4.8% allele frequency and [B] a TP53 exon 4 frameshift deletion (TP53 c.124del) with frequency 38.9%.

The CDKN2A Probe covers CDKN2A (P16) gene and flanking regions, and is labeled in gold. The Centromere 17 Probe covers the chromosome 17 centromere (D17Z1) region and is labeled in aqua. The Centromere 3 Probe covers the chromosome 3 centromere (D3Z1) region and is labeled in red. The Centromere 7 Probe covers the chromosome 7 centromere (D7Z1) region and is labeled in green.

Developed in partnership with myeloid cancer experts to the latest WHO guidance, the panel can identify novel fusion partners — providing more comprehensive and informative analyses than possible using PCR-driven methods. The figure (right) shows the consistent and confident detection of MECOM overexpression in [A] serial dilutions of HNT-34 cell line as well as [B] research and commercial samples, including positive and negative controls.